• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Role of TEM-1 β-Lactamase in the Predominance of Ampicillin-Sulbactam-Nonsusceptible in Japan.TEM-1 β-内酰胺酶在日本氨苄西林-舒巴坦不敏感中的主导作用。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02366-18. Print 2019 Feb.
2
Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended- spectrum-beta-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction.产超广谱β-内酰胺酶阴性氨苄西林-舒巴坦耐药大肠埃希菌血流感染的临床特征及 TEM-1 过度表达的作用。
Antimicrob Agents Chemother. 2011 Feb;55(2):495-501. doi: 10.1128/AAC.00797-10. Epub 2010 Dec 6.
3
Escherichia coli resistant to ampicillin/sulbactam.对氨苄西林/舒巴坦耐药的大肠杆菌。
Chemotherapy. 1992;38(6):399-404. doi: 10.1159/000239034.
4
Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.对具有不同β-内酰胺耐药表型的大肠埃希菌分离株进行氨苄西林-舒巴坦和阿莫西林-克拉维酸药敏试验。
Antimicrob Agents Chemother. 1999 Apr;43(4):862-7. doi: 10.1128/AAC.43.4.862.
5
beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.马来亚大学医学中心分离出的大肠杆菌中β-内酰胺耐药表型的测定
Malays J Pathol. 2003 Dec;25(2):113-9.
6
Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 beta-lactamase.舒巴坦联合制剂对已知TEM-1β-内酰胺酶含量的大肠杆菌分离株的活性。
J Antimicrob Chemother. 1992 Feb;29(2):222-4. doi: 10.1093/jac/29.2.222.
7
Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.在体外动态模型中氨苄西林-舒巴坦对产TEM-1β-内酰胺酶大肠杆菌作用的预测因素:酶活性与最低抑菌浓度
Antimicrob Agents Chemother. 1996 Mar;40(3):734-8. doi: 10.1128/AAC.40.3.734.
8
Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.阿莫西林-克拉维酸、氨苄西林-舒巴坦和哌拉西林-他唑巴坦对携带已知β-内酰胺酶的大肠杆菌和奇异变形杆菌菌株的体外比较活性。
Infection. 1991 Mar-Apr;19(2):106-9. doi: 10.1007/BF01645578.
9
An evaluation of susceptibility testing methods for ampicillin-sulbactam using a panel of beta-lactamase-producing bacteria.使用一组产β-内酰胺酶细菌对氨苄西林-舒巴坦药敏试验方法的评估。
APMIS. 1999 Jul;107(7):703-8. doi: 10.1111/j.1699-0463.1999.tb01464.x.
10
An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.β-内酰胺酶抑制剂组合与亚胺培南及头孢菌素对产TEM-1或TEM-2β-内酰胺酶大肠杆菌活性的体外和体内比较
J Antimicrob Chemother. 1991 Jul;28(1):61-70. doi: 10.1093/jac/28.1.61.

引用本文的文献

1
Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation.由于窄谱β-内酰胺酶和 Omp 突变,对头孢哌酮/舒巴坦和哌拉西林/他唑巴坦的敏感性降低。
Pol J Microbiol. 2022 Jun 19;71(2):251-256. doi: 10.33073/pjm-2022-023.
2
Comprehensive Genomic Survey of Antimicrobial-Resistance Bacteria in the Sewage Tank Replacement with Hospital Relocation.医院搬迁后污水池替代物中抗菌药物耐药菌的综合基因组调查
Infect Drug Resist. 2021 Dec 20;14:5563-5574. doi: 10.2147/IDR.S336418. eCollection 2021.
3
Inhibition of Class A β-Lactamase (TEM-1) by Narrow Fractions of Humic Substances.腐殖质窄馏分对A类β-内酰胺酶(TEM-1)的抑制作用。
ACS Omega. 2021 Sep 7;6(37):23873-23883. doi: 10.1021/acsomega.1c02841. eCollection 2021 Sep 21.

本文引用的文献

1
Rapid Identification of Different Escherichia coli Sequence Type 131 Clades.不同大肠杆菌序列类型131进化枝的快速鉴定
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00179-17. Print 2017 Aug.
2
Antimicrobial susceptibility of pathogens isolated from surgical site infections in Japan: Comparison of data from nationwide surveillance studies conducted in 2010 and 2014-2015.日本外科手术部位感染分离病原菌的抗菌药物敏感性:2010年及2014 - 2015年全国监测研究数据比较
J Infect Chemother. 2017 Jun;23(6):339-348. doi: 10.1016/j.jiac.2017.03.010. Epub 2017 Apr 5.
3
Population structure of Japanese extraintestinal pathogenic Escherichia coli and its relationship with antimicrobial resistance.日本肠外致病性大肠杆菌的种群结构及其与抗菌药物耐药性的关系。
J Antimicrob Chemother. 2017 Apr 1;72(4):1040-1049. doi: 10.1093/jac/dkw530.
4
Global Escherichia coli Sequence Type 131 Clade with bla Gene.携带bla基因的全球大肠杆菌序列型131进化枝
Emerg Infect Dis. 2016 Nov;22(11):1900-1907. doi: 10.3201/eid2211.160519.
5
Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.亚太地区尿路感染病原体的流行病学和抗菌药物敏感性分析:2010-2013 年监测抗菌药物耐药性趋势研究(SMART)结果。
Int J Antimicrob Agents. 2016 Apr;47(4):328-34. doi: 10.1016/j.ijantimicag.2016.01.008. Epub 2016 Feb 17.
6
β-lactamases produced by amoxicillin-clavulanate-resistant enterobacteria isolated in Buenos Aires, Argentina: a new blaTEM gene.从阿根廷布宜诺斯艾利斯分离出的对阿莫西林-克拉维酸耐药的肠杆菌产生的β-内酰胺酶:一种新的blaTEM基因。
Rev Argent Microbiol. 2014 Jul-Sep;46(3):210-7. doi: 10.1016/S0325-7541(14)70075-6. Epub 2014 Oct 15.
7
Escherichia coli ST131, an intriguing clonal group.大肠杆菌ST131,一个引人关注的克隆群。
Clin Microbiol Rev. 2014 Jul;27(3):543-74. doi: 10.1128/CMR.00125-13.
8
Global dissemination of a multidrug resistant Escherichia coli clone.全球传播的一种多重耐药大肠杆菌克隆。
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5694-9. doi: 10.1073/pnas.1322678111. Epub 2014 Mar 31.
9
Permeation rates of penicillins indicate that Escherichia coli porins function principally as nonspecific channels.青霉素的渗透速率表明大肠埃希菌的孔道蛋白主要作为非特异性通道发挥作用。
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):E2629-34. doi: 10.1073/pnas.1310333110. Epub 2013 Jun 24.
10
The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups.重新审视克莱蒙大肠杆菌噬菌体分型法:提高特异性和检测新的噬菌体群。
Environ Microbiol Rep. 2013 Feb;5(1):58-65. doi: 10.1111/1758-2229.12019. Epub 2012 Dec 24.

TEM-1 β-内酰胺酶在日本氨苄西林-舒巴坦不敏感中的主导作用。

Role of TEM-1 β-Lactamase in the Predominance of Ampicillin-Sulbactam-Nonsusceptible in Japan.

机构信息

Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

出版信息

Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02366-18. Print 2019 Feb.

DOI:10.1128/AAC.02366-18
PMID:30455244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6355572/
Abstract

We investigated the epidemiology and resistance mechanisms of ampicillin-sulbactam-nonsusceptible , focusing on the role of the TEM-1 β-lactamase. We collected all nonduplicate clinical isolates at 10 Japanese hospitals during December 2014 and examined their antimicrobial susceptibility, β-lactamases, TEM-1 transferability, TEM-1 β-lactamase activity, outer membrane protein profile, membrane permeability, and clonal genotypes. Among the 329 isolates collected, 95 were ampicillin-sulbactam nonsusceptible. Of these ampicillin-sulbactam-nonsusceptible isolates, β-lactamases conferring resistance to sulbactam, such as AmpC, were present in 33%. Hyperproduction of sulbactam-susceptible β-lactamases, TEMs with a strong promoter, were rare (5%). The remaining 59 isolates (62%) had only sulbactam-susceptible β-lactamases, including TEM-1 with a wild-type promoter ( = 28), CTX-Ms ( = 13), or both ( = 17). All 45 transconjugants from 96 donors with TEM-1 had higher ampicillin-sulbactam MICs (4 to 96 mg/liter) than the recipient (2 mg/liter). In donors with only TEM-1, TEM-1 activity correlated with the 50% inhibitory concentration of sulbactam and ampicillin-sulbactam MICs. The decreased membrane permeation of sulbactam was associated with an increased ampicillin-sulbactam MIC. The reduced permeation was partly attributable to deficient outer membrane proteins, which were observed in 57% of the ampicillin-sulbactam-nonsusceptible isolates with only TEM-1 and a wild-type promoter. Sequence type 131 (ST131) was the most common clonal type (52%). TEM-1 with a wild-type promoter primarily contributed to ampicillin-sulbactam nonsusceptibility in , with the partial support of other mechanisms, such as reduced permeation. Conjugative TEM-1 and the clonal spread of ST131 may contribute to the prevalence of Japanese ampicillin-sulbactam-nonsusceptible isolates.

摘要

我们研究了氨苄西林-舒巴坦不敏感的流行病学和耐药机制,重点关注 TEM-1 β-内酰胺酶的作用。我们在 2014 年 12 月从日本的 10 家医院收集了所有非重复的临床分离株,并检查了它们的抗菌药物敏感性、β-内酰胺酶、TEM-1 的可转移性、TEM-1 β-内酰胺酶活性、外膜蛋白谱、膜通透性和克隆基因型。在收集的 329 株分离株中,95 株对氨苄西林-舒巴坦不敏感。在这些对氨苄西林-舒巴坦不敏感的分离株中,对舒巴坦具有耐药性的β-内酰胺酶,如 AmpC,存在于 33%的菌株中。舒巴坦敏感β-内酰胺酶的过度产生,如 TEMs,其强启动子很少见(5%)。其余 59 株(62%)仅具有舒巴坦敏感的β-内酰胺酶,包括野生型启动子的 TEM-1(=28)、CTX-Ms(=13)或两者兼有(=17)。从 96 个供体的 45 个转导子中,所有带有 TEM-1 的供体的氨苄西林-舒巴坦 MIC 值(4 至 96 毫克/升)均高于受体(2 毫克/升)。在只有 TEM-1 的供体中,TEM-1 活性与舒巴坦和氨苄西林-舒巴坦 MIC 的 50%抑制浓度相关。舒巴坦的膜通透性降低与氨苄西林-舒巴坦 MIC 值升高有关。这种通透性的降低部分归因于外膜蛋白的缺乏,在只有 TEM-1 和野生型启动子的 57%的氨苄西林-舒巴坦不敏感分离株中观察到了这种情况。ST131(ST131)是最常见的克隆型(52%)。TEM-1 与野生型启动子主要导致了日本的氨苄西林-舒巴坦不敏感分离株,同时也有其他机制的部分支持,如通透性降低。可接合的 TEM-1 和 ST131 的克隆传播可能导致日本氨苄西林-舒巴坦不敏感分离株的流行。